Organon USA Inc. Newsletter
-
Organon Korea sales and customers lead named new head for Organon Malaysia
23 Dec 2024 02:25 GMT
… the new Country Lead for Organon Malaysia, effective Jan. 1, … role in the growth of Organon Korea since its inception,” … as the Country Lead for Organon Malaysia, Oh is expected … achievements.
Meanwhile, before joining Organon Korea, Oh held various leadership …
-
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
19 Dec 2024 12:46 GMT
… &kiosk=true
About Organon
Organon is an independent global … areas. In addition to Organon’s current products, the … their products by leveraging Organon’s scale and agile … fast growing international markets.
Organon has geographic scope with significant …
-
FDA approves Organon’s Vtama cream to treat atopic dermatitis in adults and children
19 Dec 2024 12:51 GMT
… Drug Administration (FDA) has approved Organon’s Vtama (tapinarof) cream, 1% … less than two months after Organon completed its acquisition of Dermavant … period.
Commenting on the authorisation, Organon’s chief executive officer, said …
-
Organon's steroid-free cream Vtama wins approval in atopic dermatitis
13 Dec 2024 23:20 GMT
-
FDA Accepts BLA for Shanghai Henlius Biotech’s and Organon’s HLX14, a Denosumab Biosimilar
08 Nov 2024 19:54 GMT
… , 2024, Shanghai Henlius Biotech and Organon announced that the FDA has … 2022, Shanghai Henlius Biotech granted Organon exclusive commercialization rights for HLX14 …
-
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
05 Nov 2024 17:04 GMT
… .
Shanghai Henlius Biotech and Organon Updates
Partners Shanghai Henlius Biotech … the aforementioned 2022 agreement, Organon holds exclusive commercialization rights for … Perjeta (pertuzumab) biosimilar candidate HLX11. Organon. News release; September 30, …
-
FDA Accepts aBLAs for Prolia® / Xgeva® Biosimilars from Organon and Teva
05 Nov 2024 17:39 GMT
On October 30, 2024, Organon announced the FDA acceptance of … ’s Prolia® / Xgeva® (denosumab). Organon licensed the commercialization rights for … proposed Prolia® biosimilar TVB-009P.
Organon and Teva’s applications join …
-
Organon Reports Results for the Third Quarter Ended September 30, 2024
31 Oct 2024 11:39 GMT
… into the call.
About Organon
Organon is an independent global healthcare … and biosimilars. In addition, Organon is pursuing opportunities to collaborate … difficulties implementing or executing on Organon’s acquisition strategy, difficulties integrating …
-
Shanghai Henlius Biotech, Organon announce FDA acceptance of BLA for HLX14
31 Oct 2024 09:19 GMT
Shanghai Henlius Biotech (Henlius) and Organon have announced the US Food … licensing and supply agreement with Organon, granting the latter with exclusive … the US.
New Jersey-based Organon is a global healthcare company …
-
FDA Accepts Organon’s Application for Prolia Biosimilar
30 Oct 2024 23:46 GMT
… treats patients with bone cancer.
Organon, which acquired the commercialization rights … other serious bone conditions.
The Organon/Shanghai Henlius Biotech application … for fracture.
In May 2024, Organon/Shanghai Henlius Biotech announced …
About
© 1995-2025